Invitrogen acquisition
This article was originally published in The Gray Sheet
Executive Summary
InforMax' Vector and Vector NTI family of products will simplify use of Invitrogen's kits for gene identification, cloning, expression and analysis, under a $42 mil. all-cash transaction, expected to close by year-end, the firms say. InforMax President, Chairman and CEO Andrew Whiteley will remain president of InforMax. Tender offer will give Invitrogen 100% of InforMax outstanding common stock, valued at $1.36 per share...